TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On November 8, 2017, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the third quarter ended September 30, 2017. TG also announced that on Wednesday, November 8, 2017 at 8:30am ET, TG would host an investor conference call during which the Company would provide a brief overview of its third quarter financial results and provide a business outlook for the remainder of 2017. A copy of such press release is being furnished as Exhibit 99.1.
Item 9.01 Financial Statements And Exhibits.
(d) Exhibits.
99.1
Press release issued by TG Therapeutics, Inc., dated November 8, 2017.
TG THERAPEUTICS, INC. ExhibitEX-99.1 2 v110817_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TG Therapeutics,…To view the full exhibit click here
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
